Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia

Ibrutinib is the first Bruton’s tyrosine kinase (BTK) inhibitor, which showed significant clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients regardless of cytogenetic risk factors. Recent results of phase III clinical trials in treatment-naïve CLL p...

Descripción completa

Detalles Bibliográficos
Autores principales: Puła, Bartosz, Gołos, Aleksandra, Górniak, Patryk, Jamroziak, Krzysztof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966427/
https://www.ncbi.nlm.nih.gov/pubmed/31766355
http://dx.doi.org/10.3390/cancers11121834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966427/
https://www.ncbi.nlm.nih.gov/pubmed/31766355
http://dx.doi.org/10.3390/cancers11121834

Ejemplares similares